Literature DB >> 24357157

Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis.

Xiaoxia Gou1, Haixia Chen, Feng Jin, Weili Wu, Yuanyuan Li, Jinhua Long, Xiuyun Gong, Mengyalan Luo, Ting Bi, Zhuolin Li, Qianyong He.   

Abstract

The objectives of this study are to investigate the expressions of matrix metalloproteinase inducing factor (CD147), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) in laryngeal tumor tissues and its significant correlation with tumor infiltration, metastasis and prognosis. Laryngeal tumor tissue from 48 laryngeal cancer patients with complete clinical information was collected. The laryngitis tissue from 15 patients were collected as control group. Immunohistochemical analysis for CD147, MMP-2 and MMP-9 was performed for all the tissue. The results showed the expression rates of CD147, MMP-2 and MMP-9 in laryngeal carcinoma were 87.5 %, 75.0 % and 79.2 % respectively, significantly higher than those (26.7 %, 6.7 %, and 33.3 % respectively) in the control group are (P < 0.01). High expression of CD147, MMP-2 and MMP-9 related to the clinical stages and lymphatic metastasis of laryngeal carcinoma. Univariate survival analysis showed that the 5-year survival of laryngeal carcinoma patients with low expression of CD147, MMP-2 and MMP-9was 83.3 %, 83.3 % and 90 % respectively, while the patients with high expression had 5-year survival at 25 %, 7.7 % and 18.2 % respectively (P < 0.05). Multiple regression analysis showed that high expression of MMP-9 was independently associated with poor prognosis (P < 0.05). High expression of CD147, MMP-2 and MMP-9 were related with laryngeal carcinoma invasion and metastasis. High expressions of CD147, MMP-2 and MMP-9 were all predictive factors of poor prognosis of laryngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24357157     DOI: 10.1007/s12253-013-9720-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  14 in total

1.  EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface.

Authors:  H Guo; R Li; S Zucker; B P Toole
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

Review 2.  Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression.

Authors:  Kazuki Nabeshima; Hiroshi Iwasaki; Kaori Koga; Hironobu Hojo; Junji Suzumiya; Masahiro Kikuchi
Journal:  Pathol Int       Date:  2006-07       Impact factor: 2.534

3.  A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.

Authors:  Jing Xu; Zhong-Yang Shen; Xin-Guo Chen; Qing Zhang; Hui-Jie Bian; Ping Zhu; Hui-Yun Xu; Fei Song; Xiang-Min Yang; Li Mi; Qing-Chuan Zhao; Rong Tian; Qiang Feng; Si-He Zhang; Yu Li; Jian-Li Jiang; Ling Li; Xiao-Ling Yu; Zheng Zhang; Zhi-Nan Chen
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 4.  Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression.

Authors:  Sonata Jodele; Laurence Blavier; Janet M Yoon; Yves A DeClerck
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

5.  Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells.

Authors:  Yasuhito Kato; Tsuyoshi Yamashita; Mutsuo Ishikawa
Journal:  Oncol Rep       Date:  2002 May-Jun       Impact factor: 3.906

6.  Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing.

Authors:  Ye-Hong Kuang; Xiang Chen; Juan Su; Li-Sha Wu; Ji Li; Jing Chang; Ying Qiu; Zhe-Sheng Chen; Takuro Kanekura
Journal:  J Proteome Res       Date:  2008-09-25       Impact factor: 4.466

7.  Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro.

Authors:  Yutaka Noguchi; Takashi Sato; Michiko Hirata; Tetsuaki Hara; Koso Ohama; Akira Ito
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

8.  HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection.

Authors:  Yu Li; Jing Xu; Ling Chen; Li Chen; Wei-De Zhong; Zheng Zhang; Li Mi; Yang Zhang; Cheng-Gong Liao; Hui-Jie Bian; Jian-Li Jiang; Xiang-Min Yang; Xiao-Yan Li; Chun-Mei Fan; Ping Zhu; Li Fu; Zhi-Nan Chen
Journal:  Histopathology       Date:  2009-05       Impact factor: 5.087

9.  Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells.

Authors:  Li Jia; Wei Wei; Jun Cao; Henggui Xu; Xiaoyan Miao; Jianing Zhang
Journal:  Ann Hematol       Date:  2009-01-01       Impact factor: 3.673

10.  Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN.

Authors:  Yi Tang; Prabakaran Kesavan; Marian T Nakada; Li Yan
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

View more
  16 in total

1.  The role of mechano-growth factor E peptide in the regulation of osteosarcoma.

Authors:  Jin Shang; Xin Fan; Huan Liu
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

Review 2.  CD147 and glioma: a meta-analysis.

Authors:  Hui Li; Zhouhuan Xi; Xuejiao Dai; Wenyue Wu; Yanwen Li; Yanting Liu; Hanwen Zhang
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130

3.  Kinetochore-associated protein 1 promotes the invasion and tumorigenicity of cervical cancer cells via matrix metalloproteinase-2 and matrix metalloproteinase-9.

Authors:  Caimei Wang; Yiyuan Wang; Congrong Liu; Xiaoyu Meng; Zhongxia Hang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 4.  The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.

Authors:  Lijuan Xiong; Carl K Edwards; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

5.  MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma.

Authors:  John Zeng-Hong Li; Wei Gao; Wen-Bin Lei; Jing Zhao; Jimmy Yu-Wai Chan; William Ignace Wei; Wei-Kuen Ho; Thian-Sze Wong
Journal:  Oncotarget       Date:  2016-09-06

6.  The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies.

Authors:  Hengwei Fan; Wanwan Yi; Chenxing Wang; Jisheng Wang
Journal:  Oncotarget       Date:  2017-07-31

7.  Melittin inhibits the invasion of MCF-7 cells by downregulating CD147 and MMP-9 expression.

Authors:  Jianjun Wang; Fengyu Li; Jiang Tan; Xuewei Peng; Lili Sun; Ping Wang; Shengnan Jia; Qingmiao Yu; Hongliang Huo; Hongyan Zhao
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

8.  EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival.

Authors:  Luís Silva Monteiro; Maria Leonor Delgado; Sara Ricardo; Fernanda Garcez; Barbas do Amaral; José Júlio Pacheco; Carlos Lopes; Hassan Bousbaa
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

Review 9.  Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis.

Authors:  Cory D Bovenzi; James Hamilton; Patrick Tassone; Jennifer Johnson; David M Cognetti; Adam Luginbuhl; William M Keane; Tingting Zhan; Madalina Tuluc; Voichita Bar-Ad; Ubaldo Martinez-Outschoorn; Joseph M Curry
Journal:  Biomed Res Int       Date:  2015-12-08       Impact factor: 3.411

10.  Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.

Authors:  Hui Li; Dongwen Wu; Shupeng Shi; Yadong Xu; Ling Wei; Jing Liu; Yanting Liu
Journal:  Oncotarget       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.